The DOI matches its Crossref record.
Outrageous prices of orphan drugs: a call for collaboration
Abstract
Few instances of a single act of legislation have shifted industrial policy in the pharmaceutical industry like the Orphan Drugs Act did when it was signed in the USA in 1983. The Act was written to facilitate the development of drugs for rare diseases and health conditions, and the incentives provided by the Act, such as 7 year exclusivity, tax credits of up to 50% of research and development costs, and access to research and development grants, resulted in the US Food and Drug Administration (FDA) approving 575 drugs and biological products for rare diseases between 1983 and 2017—a real success. In 2000, the European Commission passed similar legislation for orphan medicinal products (OMPs). As a matter of fact, the diseases, not the drugs, are the orphans because all drugs are very expensive, having marrying this success story (table). Although we are dealing with rare diseases, the increasing number of new OMPs introduced each year is beginning to threaten the sustainability of healthcare systems. The socioeconomic, ethical, and legal implications of this state of affairs have been analysed ex tensively. We have previously discussed these implications, and here we concentrate on possible corrective actions. Although the focus here is on OMPs, our recommendations are applicable to other drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Ferreira, C. R. (2019) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.61124 · Cited by 498
How much does it cost to research and develop a new drug? A systematic review and assessment
Schlander, M., Hernandez-Villafuerte, K., Cheng, C.-Y., Mestre-Ferrandiz, J., & Baumann, M. (2021) · PharmacoEconomics · doi:10.1007/s40273-021-01065-y · Cited by 360
Adachi, T., El-Hattab, A. W., Jain, R., Nogales Crespo, K. A., Quirland Lazo, C. I., Scarpa, M., Summar, M., & Wattanasirichaigoon, D. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20064732 · Cited by 168
“Some of the most expensive drugs on the market are targeted to treat RDs [21].”
Background
Metadata
- Authors
- Luzzatto, L., Hyry, H. I., Schieppati, A., Costa, E., Simoens, S., Schaefer, F., Roos, J. C. P., Merlini, G., Kääriäinen, H., Garattini, S., Hollak, C. E., Remuzzi, G., Barbui, T., Benigni, A., Costa, E., Daina, E., Garattini, S., Gramaglia, D., Hollak, C. E. M., Hyry, H., Kaarinen, H., Licht, C., Luzzatto, L., Merlini, G., Notaro, R., Remuzzi, G., Schaefer, F., Schieppati, A., & Simoens, S.
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2018-09
- Volume
- 392
- Issue
- 10149
- Pages
- 791-794
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2884486468
- Cited by
- 158
- References
- 0
- FWCI
- 28.59
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Outrageous prices of orphan drugs: a call for collaboration. https://app.cochat.ai/papers/10.1016/s0140-6736(18)31069-9
- The paper
- Luzzatto, L., Hyry, H. I., Schieppati, A., Costa, E., Simoens, S., Schaefer, F., Roos, J. C. P., Merlini, G., Kääriäinen, H., Garattini, S., Hollak, C. E., Remuzzi, G., Barbui, T., Benigni, A., Costa, E., Daina, E., Garattini, S., Gramaglia, D., Hollak, C. E. M., . . . Simoens, S. (2018). Outrageous prices of orphan drugs: a call for collaboration. The Lancet. https://doi.org/10.1016/s0140-6736(18)31069-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.